Torrent Pharmaceuticals to acquire branded business of India and Nepal from Unichem

04 Nov 2017 Evaluate

Torrent Pharmaceuticals has entered into a definitive binding agreement with Unichem Laboratories to acquire its branded business of India and Nepal for a consideration of Rs 3,600 crore, pursuant to the approval from the Board of Directors of the company. The transaction is ongoing concern basis by way of Slump sale. Torrent will fund the acquisition through a mix of internal accruals and bank borrowings.

Unichem’s India business comprises of a portfolio of more than 120 brands in India and Nepal, manufacturing plant at Sikkim catering to these markets and all the employees engaged in the said business.

This transaction will open doors for Torrent to enter into the OTC segment with the brand ‘Unienzyme’ and the company will be a dominant player in the Digestive Enzyme market and will be amongst the top three players in the segments of Anti-Hypertensive, Anti-Depressants and Tranquilizers.

With this deal, Torrent will enter the list of top pharma firms in the Indian Pharma market (IPM) and will be ranked No 5 in the IMS. The acquisition helps Torrent to consolidate its market share in terms of sales which will increase from current 2.4% to 3.4% in the IPM.



Torrent Pharma Share Price

3757.95 -23.60 (-0.62%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×